Universal influenza vaccines are futile when benchmarked against seasonal influenza vaccines

Article Infectious Diseases

Efficacy and safety of a universal influenza A vaccine (MVA-NP+M1) in adults when given after seasonal quadrivalent influenza vaccine immunisation (FLU009): a phase 2b, randomised, double-blind trial

Thomas G. Evans et al.

Summary: In a study conducted in Australia, inducing additional T-cell responses through a recombinant viral-vectored vaccine did not provide added benefit to standard influenza vaccination. The vaccine was well tolerated and did not have any vaccine-associated serious adverse events.

LANCET INFECTIOUS DISEASES (2022)

Add to Collection

Article Multidisciplinary Sciences

Quadrivalent influenza nanoparticle vaccines induce broad protection

Seyhan Boyoglu-Barnum et al.

Summary: Computational design of nanoparticle immunogens can induce potent and broad antibody responses against diverse influenza viruses, including neutralizing antibody responses to vaccine-matched strains and broadly protective antibody responses to heterologous viruses. These novel vaccines have the potential to replace traditional seasonal vaccines.

NATURE (2021)

Add to Collection

Article Immunology

Efficacy and Safety of a Modified Vaccinia Ankara-NP+M1 Vaccine Combined with QIV in People Aged 65 and Older: A Randomised Controlled Clinical Trial (INVICTUS)

Chris Butler et al.

Summary: The study aimed to evaluate the safety and immunogenicity of a T-cell directed vaccine in older people, finding that the MVA-NP+M1 vaccine was well tolerated in those aged 65 years and over, although the trial was halted after one season.

VACCINES (2021)

Add to Collection

Article Immunology